The abstract is read at the publisher; the summary is JClub's.
LNP-delivered spCas13b RNPs targeting BIRC5 achieve ~80% encapsulation efficiency and silence endogenous survivin in three pancreatic cancer cell lines.
- Why it matters: PDAC often resists chemotherapy, and survivin (BIRC5) overexpression is linked to tumor survival and gemcitabine resistance, creating a need for RNA-targeted sensitization.
- What they did: The team optimized ionizable lipid formulations to encapsulate preassembled spCas13b RNPs, maintaining gene-silencing activity after 7 days at 4{degrees}C, then tested BIRC5 knockdown in vitro and in a PANC-1 xenograft.
- The result: In gemcitabine-resistant PANC-1 cells, BIRC5 silencing synergistically increased gemcitabine cytotoxicity, and only the combined Cas13b RNP-LNP plus gemcitabine treatment significantly inhibited tumor growth without apparent systemic toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.